Amgen Inc.
PAC1 ANTIBODIES AND USES THEREOF

Last updated:

Abstract:

The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

Status:
Application
Type:

Utility

Filling date:

21 Dec 2021

Issue date:

23 Jun 2022